Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 442

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Open access
Popovici-Muller, Janeta, Lemieux, René M., Artin, Erin, Saunders, Jeffrey O., Salituro, Francesco G., Travins, Jeremy, Cianchetta, Giovanni, Cai, Zhenwei, Zhou, Ding, Cui, Dawei, Chen, Ping, Straley, Kimberly, Tobin, Erica, Wang, Fang, David, Muriel D., Penard-Lacronique, Virginie, Quivoron, Cyril, Saada, Véronique, de Botton, Stéphane, Gross, Stefan, Dang, Lenny, Yang, Hua, Utley, Luke, Chen, Yue, Kim, Hyeryun, Jin, Shengfang, Gu, Zhiwei, Yao, Gui, Luo, Zhiyong, Lv, Xiaobing, Fang, Cheng, Yan, Liping, Olaharski, Andrew, Silverman, Lee, Biller, Scott, Su, Shin-San M., Yen, Katharine·2018·ACS Medicinal Chemistry Letters

Abstract

Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation. IDH1 mutations have been described in an array of hematologic malignancies and solid tumors. Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo. Preliminary data from phase 1 clinical trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clinical activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsmedchemlett.7b00421

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 442

Metadata

Authors
Popovici-Muller, J., Lemieux, R. M., Artin, E., Saunders, J. O., Salituro, F. G., Travins, J., Cianchetta, G., Cai, Z., Zhou, D., Cui, D., Chen, P., Straley, K., Tobin, E., Wang, F., David, M. D., Penard-Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Gross, S., Dang, L., Yang, H., Utley, L., Chen, Y., Kim, H., Jin, S., Gu, Z., Yao, G., Luo, Z., Lv, X., Fang, C., Yan, L., Olaharski, A., Silverman, L., Biller, S., Su, S.-S. M., & Yen, K.
Venue
ACS Medicinal Chemistry Letters
Published
2018-01-19
Volume
9
Issue
4
Pages
300-305
ISSN
1948-5875 (ISSN-L)
OpenAlex
W2785262117
Cited by
442
References
13
FWCI
25.68
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. https://app.cochat.ai/papers/10.1021/acsmedchemlett.7b00421
The paper
Popovici-Muller, J., Lemieux, R. M., Artin, E., Saunders, J. O., Salituro, F. G., Travins, J., Cianchetta, G., Cai, Z., Zhou, D., Cui, D., Chen, P., Straley, K., Tobin, E., Wang, F., David, M. D., Penard-Lacronique, V., Quivoron, C., Saada, V., de Botton, S., . . . Yen, K. (2018). Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.7b00421

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.